LAVA Therapeutics ( (LVTX) ) has issued an announcement.
On February 20, 2025, LAVA Therapeutics announced a restructuring plan to extend its capital resources and evaluate strategic alternatives, including a 30% workforce reduction expected to be completed by July 31, 2025. The company aims to maximize shareholder value by exploring various strategic options such as in-licensing, sales, or mergers, while continuing its clinical study of LAVA-1266 and maintaining partnerships with Pfizer and Johnson & Johnson.
More about LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company focused on advancing its proprietary Gammabody® platform to develop a portfolio of bispecific gamma-delta T cell engagers for the potential treatment of solid tumors and hematologic malignancies. The company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 T cell anti-tumor effector functions upon cross-linking to tumor-associated antigens.
YTD Price Performance: -8.74%
Average Trading Volume: 105,273
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $24.71M
Learn more about LVTX stock on TipRanks’ Stock Analysis page.